We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
- Authors
Harvey, Vernon J.; Slevin, Maurice L.; Ponder, Bruce A. J.; Blackshaw, Anthony J.; Wrigley, Peter F. M.; Harvey, V J; Slevin, M L; Ponder, B A; Blackshaw, A J; Wrigley, P F
- Abstract
Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil. One partial response of 24 months was seen. Eleven patients were treated with single-agent Adriamycin (doxorubicin) after progression on 5-fluorouracil, and one partial response of 34 months was seen. It is concluded that 5-fluorouracil has only minimal activity in diffuse malignant mesothelioma. Preliminary data suggest that Adriamycin has little activity as a second-line agent.
- Subjects
MESOTHELIOMA; CLINICAL drug trials; CLINICAL trials; DOXORUBICIN; TIME; FLUOROURACIL; PERITONEUM tumors; PLEURAL tumors
- Publication
Cancer (0008543X), 1984, Vol 54, Issue 6, p961
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19840915)54:6<961::AID-CNCR2820540602>3.0.CO;2-B